Pancreatic cancer: adjuvant FOLFIRINOX tops gemcitabine for DFS, OS

  • New Engl J Med

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adjuvant therapy with a modified version of FOLFIRINOX yielded significantly longer DFS and OS vs gemcitabine among patients with resected pancreatic cancer and no evidence of metastasis.
  • Benefit came at a cost of increased toxicity.

Why this matters

  • Modified-FOLFIRINOX may become a new therapy option for resected pancreatic cancer.

Study design

  • Multicenter, randomized, phase 3 trial (n=493) of gemcitabine (1000 mg/square meter of body-surface area) or modified-FOLFIRINOX (oxaliplatin [85 mg/square meter], irinotecan [180 mg/square meter], leucovorin [400 mg/square meter], and fluorouracil [2400 mg/square meter]) over 24 weeks.
  • DFS, the primary outcome, defined as absence of cancer-related event, second cancer, or death from any cause.
  • Funding: R&D Unicancer; others.

Key results

  • Median follow-up, 33.6 months.
  • 3-year DFS was higher with modified FOLFIRINOX vs gemcitabine (39.7% vs 21.4%).
    • Median DFS was 42% longer (21.6 months [95% CI, 17.7-27.6] vs 12.8 months [95% CI, 11.7-15.2]).
    • Stratified HR, 0.58 (P<.001>
  • 3-year OS was higher with modified FOLFIRINOX vs gemcitabine (63.4% vs 48.6%).
    • Median OS was 36% longer (54.4 months [95% CI, 41.8-not reached] vs 35.0 months [95% CI, 28.7-43.9]).
    • Stratified HR, 0.64 (P=.003).
  • More grade 3/4 adverse events with modified FOLFIRINOX (75.9% vs 52.9%).

Limitations

  • None identified.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit